Key result
Female sex is linked to ~35% lower MACCE risk at 30 months following contemporary PCI.
Why the study?
Sex differences in clinical outcomes remain controversial in patients treated with a drug-eluting stent.
Does female sex reduce MACCE and major bleeding in patients treated with a drug-eluting stent?
Observational (n=6,266)
Yes
Does female sex reduce MACCE and major bleeding in patients treated with a drug-eluting stent?
In a contemporary Japanese PCI registry, female sex was associated with a lower adjusted risk of MACCE at 30 months compared to male sex, with no difference in major bleeding.
Answers are grounded in this paper and cite their sources.
Should not yet change sex-specific PCI risk models; extends observational data on lower MACCE risk in women but requires prospective validation.
BACKGROUND: Sex differences in clinical outcomes remain controversial in patients treated with a drug-eluting stent (DES). OBJECTIVES: inhibitors. METHODS: The PENDULUM (Platelet rEactivity in patieNts with DrUg eLUting stent and balancing risk of bleeding and ischeMic event) registry was a prospective, multicenter, PCI registry in Japan. The primary endpoints were major adverse cardiac and cerebrovascular events (MACCE) and major bleeding (Bleeding Academic Research Consortium types 3 and 5) 30 months after the index PCI. RESULTS: Of the 6,266 patients included in this subgroup analysis, 1,357 patients (21.7%) were women. The incidences of MACCE and major bleeding at 30 months were similar between the sexes (MACCE: 9.4% vs 9.4%, HR: 1.00 [95% CI: 0.82-1.22]; P = 1.000; major bleeding: 4.2% vs 4.5%, HR: 1.07 [95% CI: 0.81-1.43]; P = 0.628). After adjustment, female sex was associated with lower incidences of MACCE at 30 months (adjusted HR: 0.65 [95% CI: 0.51-0.82]; P < 0.001). There was no interaction between sex and high bleeding risk for MACCE and major bleeding at 30-month follow-up (P for interaction = 0.926 and 0.617, respectively). CONCLUSIONS: inhibitors. There was no interaction between high bleeding risk and sex for ischemic and bleeding outcomes. (Platelet rEactivity in patieNts with DrUg eLUting stent and balancing risk of bleeding and ischeMic event; UMIN000020332).
No takes yet. Share an insight, caveat, or question.
Kogame et al. (2025) conducted an observational in Coronary artery disease requiring percutaneous coronary intervention (PCI) (n=6,266). Female sex vs. Male sex was evaluated on Major adverse cardiac and cerebrovascular events (MACCE) at 30 months (adjusted HR 0.65, 95% CI 0.51-0.82, p=<0.001). Female sex was independently associated with a 35% lower risk of major adverse cardiac and cerebrovascular events at 30 months compared to male sex in patients undergoing contemporary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: